Abstract
Introduction
Over 5.1 million Americans have heart failure (HF), a devastating disease associated with high morbidity, mortality, and cost. [1] Despite advances in therapies, only 50% of patients survive 5 years after diagnosis with HF. [2] The estimated cost of HF was $32 billion in 2013 with projections predicting $70 billion by 2030. [1, 3] In an attempt to encourage prevention and identify people at risk for HF, the American College of Cardiology (ACC)/American Heart Association (AHA) defined Stage A HF as people without HF symptoms but with related comorbid diseases conferring high risk for developing HF, such as coronary heart disease (CHD), diabetes mellitus, hypertension, or chronic kidney disease. [4] However, adequate control of risk factors among US adults with Stage A HF is unknown.
While prevention has been the focus of CHD and diabetes for decades, HF prevention lags behind with new estimates suggesting 1 in 33 people will have HF by 2030. [3] HF prevention involves adjusting lifestyle factors such as salt intake and weight, risk factor control (body mass index, blood pressure, cholesterol, blood sugar), and the use of medications proven to curb progression to HF. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] While aggressive risk factor control is recommended in Stage A HF to prevent HF progression, the degree of control and rates of therapy in this population, along with the factors associated with risk reduction, have never been determined in the US population.
The purpose of the present study was to characterize US adults with Stage A HF in a nationally representative population, using the National Health and Nutrition Examination Survey (NHANES) conducted from 2007-2010. Additionally, we examined the achievement of risk factor control, the use of pharmacologic interventions with known efficacy in delaying HF onset, and the demographic and socioeconomic variables associated with medication use and poor control of risk factors.
Methods

Study Population
The NHANES are cross-sectional studies conducted by the National Center for Health Statistics (NCHS). The study population was recruited via mobile examination centers, which visit US communities selected using a complex, multistage sampling design to represent the age, sex, and racial/ethnic distribution of the US. In this study, we used the interviews, physical examinations, and laboratory measurements gathered by the continuous NHANES surveys (2007) (2008) (2009) (2010) ) from participants age 20 years and older. These studies were approved by the NCHS Research Ethics Review Board and informed consent was obtained from all participants. [17] Stage A Heart Failure Stage A HF was defined among participants without a diagnosis of heart failure as any of the following self-reported conditions that were identified by a doctor or other health professional: CHD/myocardial infarction (MI), diabetes mellitus, hypertension, or chronic kidney disease. We used self-report rather than laboratory or anthropometric measures because these represented a population for which a physician or health professional had identified a Stage A HF condition.
Heart Failure Risk Factors
We examined risk factors known to be associated with the progression of HF that also had wellestablished treatment guidelines. Dietary sodium intake was determined via 24-hour dietary recall interviews, initially administered in-person then followed by a telephone call 3-10 days later. Sodium intake was dichotomized as <2000 mg/d and 2000 mg/d. [18] Body mass index (BMI) was determined by measuring standing height and weight and stratified by obese (BMI 30 kg/m 2 ) or not obese (BMI <30 kg/m 2 ). Low density lipoprotein cholesterol (LDL) was estimated in a subsample of NHANES participants using the Friedewald equation [19] and dichotomized according to ATP III guidelines (<100 mg/dL vs. 100 mg/dL) with an alternative guideline cutpoint of 70 mg/dL as well. [20] Hemoglobin A1c was dichotomized as <7% or 7%. Control of blood pressure was determined by systolic blood pressure (SBP) <140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg among persons with a prior diagnosis of hypertension. [21] We examined two targets for blood pressure control in participants with a prior diagnosis of diabetes or chronic kidney disease based on the more stringent JNC VII (SBP <130 and DBP <80 mm Hg) or the 2014 Hypertension guidelines (SBP <140 and DBP <90 mm Hg). [21, 22] Smoking status was examined in categories of never, former, or current. Alcohol use was examined in categories of never, former, non-excessive current, or excessive current. [23] Demographic and Socioeconomic Factors Age, sex, and race/ethnicity information were collected from all participants. Race/ethnicity was characterized as non-Hispanic white, non-Hispanic black, Mexican American, Hispanic, and Other.
[17] Socioeconomic factors examined were family income, health insurance, and education level. Self-reported annual family income data was collected from study participants and dichotomized as $20,000 or <$20,000. Health insurance coverage was based on an affirmative response to the following question: "Are you covered by health insurance or some other kind of health care plan?" Education level was ascertained with the question "What is the highest grade or level of school you have received?" Educational attainment was subsequently dichotomized as some college or < some college.
Medication Use
Participants were asked to bring their medication bottles to the examination center. Medications used in the past 30 days were recorded by NHANES staff. In this study, we grouped medications in the following three categories: angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists (ARBs), HMG-CoA reductase inhibitors (statins), or betaadrenergic blocking agents (beta-blockers).
Statistical Analyses
All analyses were performed using the sample weights, primary sampling units, and strata in concordance with NCHS recommendations to account for the NHANES complex sampling design. [24] Standard errors were determined for all metrics using the Taylor series (linearization) method. Prevalence ratios were estimated via Poisson regression, which provides a more accurate estimate of prevalence than logistic regression. [25] Analyses were performed with Stata 11.1 (StataCorp LP, College Station, TX).
Characteristics of NHANES participants with Stage A HF were determined using weighted means or prevalence estimates along with standard errors. We also evaluated the prevalence and number of US adults with Stage A HF and achievement of risk factor targets. Poisson regression and prevalence ratios were used to examine the association between family income $20,000, health insurance, or education some college and the achievement of recommended risk factor targets. Poisson models were nested as follows. Model 1 was adjusted for age, sex, and race/ethnicity, while Model 2 was adjusted for Model 1 and family income, health insurance status, and education level. We also explored demographic factors associated with meeting risk factor targets, adjusting for Model 2 covariates and using forest plots.
In order to maintain consistency with the CHD/MI category, the estimates for LDL were made using the standard 2-year weights rather than the recommended subsample weights. A sensitivity analysis evaluating the LDL using the recommended weighting scheme yielded virtually identical results. Table 2 . The number of US adults in 2007-2010 with Stage A HF was over 75 million, corresponding to 33% of the US adult population (Table 3) .
Results
[33] Examination of modifiable risk factors found that sodium intake was >2,000 mg of salt per day in 72% of these participants. Nearly half were obese with an additional 32% overweight. Among adults with CHD or prior MI, 36.3% had LDL 100 mg/dL and 78.5% had LDL 70 mg/dL. In Stage A HF patients with diabetes, the prevalence of HbA1c >7% was 44%. Furthermore, 49.2% had a SBP 130 or DBP 80 mm Hg while 26.9% had a SBP 140 or DBP 90 mm Hg. Of those with hypertension, 30.8% had a SBP 140 or DBP 90 mm Hg. In those with kidney disease, 40.0% had SBP 130 or DBP 80 mm Hg while 18.2% had SBP 140 or DBP 90 mm Hg. With regards to medications, in those with CHD/MI, only 45.9% were taking ACE inhibitors/ARBs, 58.6% were taking statins, and 51.8% were taking beta-blockers. ACE inhibitor/ARB use was also determined in participants with diabetes, of whom 50.8% were taking this class of medications. Fig 1 shows a stratified analysis of risk factors by age, sex, and race. Sodium intake was lower with increasing age. Women more commonly consumed <2,000 mg of sodium compared with men (PR: 0.83; 95% CI: 0.80, 0.86; P <0.001). With regard to race, non-Hispanic white participants were the most likely to consume 2,000 mg of sodium. BMI was also lower with age, while women and non-Hispanic blacks were more likely to have a BMI 30, with PR 1.11 (95% CI: 1.01, 1.21; P = 0.03) and 1.16 (CI 1.07, 1.25; P <0.001), respectively.
For LDL in those with CHD or a prior MI, there was a trend towards better control in participants >30 years (Fig 1) . In US adults with a diagnosis of diabetes, Mexican-Americans were more likely to have HbA1c 7%. In the same group with diabetes, non-Hispanic black adults had a PR of 1.54 (95% CI 1.20, In US adults with Stage A HF, after adjustment for demographic and socioeconomic factors, income $20,000 was associated with a sodium intake 2,000 mg while insurance status and education level was not associated with salt intake (Table 4 ). The prevalence of BMI 30 kg/ m 2 was higher in those with health insurance (PR 1.13, P = 0.05) and lower in those with some college education (PR 0.90; P = 0.04). In those with prior CHD/MI, income $20,000/year and health insurance were inversely associated with LDL 100 mg/dL with PRs of 0.58 (P = 0.03) and 0.56 (P = 0.03), respectively. Having health insurance was also inversely correlated with uncontrolled blood pressure with PR 0.70 (P = 0.002). Table 5 shows socioeconomic factors that are associated with appropriate treatment for US adults with Stage A HF. Income $20,000/year was positively associated with statin use among US adults with prior CHD/MI. Health insurance was associated with beta-blocker use in the same population. In contrast, education was not associated with medication use.
Discussion
Based on a survey of US adults, one in three adults had been told by a health professional that they have a condition consistent with Stage A HF, representing approximately 75 million people. Similarly, in patients with known CHD or prior MI, only half are on medications shown to be beneficial for secondary prevention and to prevent progression to later stage HF. While having health insurance was inversely associated with uncontrolled LDL and BP, education level was not associated with improved control of any modifiable HF risk factors except BMI. Participants with lower income had higher cholesterol and were less likely to be on a statin, though reported lower sodium intake than higher income participants.
The ACC/AHA stages of HF characterize the progression of HF from pre-clinical to endstage disease. For Stage A HF, the current guidelines recommend counseling, risk factor reduction, and control of concurrent diseases. Hypertension is the most common risk factor for HF, shown to have a population attributable risk of 39% in men and 59% in women. [34] , [35] Men with hypertension have a higher lifetime risk of developing HF, compared to normotensive men. [36] Despite being diagnosed with hypertension, over 30% of Stage A HF patients during the surveyed period had blood pressure over the targets set by JNC VII and the 2014 Hypertension guidelines. [21, 22] We found similar findings for patients with diabetes, another wellknown risk factor for HF. [37] , [38] Control of diabetes is an important predictor of new onset HF, with every 1% increase in HbA1c correlating to a 8-19% increase in HF incidence. [5] [6] [7] In addition to controlling hyperglycemia, tighter control of blood pressure is important to prevent HF and led to a 56% reduction in heart failure risk in those with diabetes. [8] Several studies have shown that blocking the renin-angiotensin system in persons with diabetes can decrease the incidence of HF, with losartan leading to 32-41% risk reduction. [9, 10] In our population, only half of the participants with diabetes were prescribed an ACE inhibitor or ARB and only 51.6% had a HgbA1c <7.0. Similarly, treating CHD and lowering cholesterol are important ways to prevent the progression from Stage A to clinical HF. In people with CHD without HF, simvastatin reduces the incidence of HF after 5 years of follow-up from 10.3% to 8.3%. [11] Reduction of LDL cholesterol in stable CHD with high doses of atorvastatin was also shown to reduce heart failure hospitalizations by 26%. [12] Unfortunately, only 21% of the study participants with CHD/MI achieved an LDL <70 mg/dL, likely in part due to only 58% being on a statin. The use of ACE inhibitors after an MI reduce the incidence of HF by 39-46% in those without HF. [13] [14] [15] In those intolerant to ACE inhibitors, ARBs are considered a reasonable substitute-but the evidence for ARBs preventing HF in patients with CHD/MI is less clear. [39] , [40] While not tested in Stage A HF, metoprolol succinate helps to prevent remodeling in people with Stage B HF, or asymptomatic LV dysfunction. [16] Despite the evidence for preventing HF in those with CHD/MI, only about half are prescribed ACE inhibitors/ARBs or beta-blockers.
In addition to controlling comorbid disease, the ACC guidelines include encouraging healthy lifestyle for Stage A HF. In the Physicians' Health Study, healthy lifestyle habits including normal body weight (BMI < 25) were associated with lower lifetime risk of heart failure. [36] Compared to those with normal BMI, obese subjects had twice the risk of developing heart failure, with a graded relationship shown between BMI and HF incidence including those in the overweight category. [41] BMI also plays a role in the effect of dietary sodium on HF Therapy of Stage A Heart Failure development, with sodium intake of >2,600 mg/day compared to <1,200 mg/day associated with a 1.43 relative risk for HF in overweight subjects.
HF is an expensive disease, and requires some degree of health literacy, self-care, and access to providers to prevent hospitalizations and poor health outcomes. Lower socioeconomic status (SES) is associated with a higher risk of incidence HF by 30-50%. [42] , [43] Our results suggest that control of hypertension, diabetes, and BMI is not different in lower income subjects with Stage A HF. However, lower income was associated with not being appropriately treated for CHD/MI. This corresponds to previous studies of people with CHD showing lower rates of secondary prevention and revascularization in lower SES groups. [44] , [45] While education level was not associated with control of comorbid diseases or medication use in Stage A HF, health insurance was associated with control of hypertension and cholesterol as well as appropriate medication use in CHD/MI. This study has some important limitations that warrant discussion. First, our definition of stage A HF is limited. Due to the absence of echocardiogram data, we likely include a number of participants with stage B HF. Conversely, we were unable to include adults with prior exposure to cardiotoxic medications, another subset of Stage A HF. Second, we utilize self-reported physician or health professional diagnoses to identify stage A HF. While this ensured that at least at some point both the study participant and a health provider were aware of a HF-predisposing condition, we did not include subclinical cases. By not including subclinical cases, we likely underestimate the prevalence of Stage A HF in US adults. Finally, the NHANES are cross-sectional studies. As a result, we are unable to make causal inferences.
Despite these limitations, our study has several important strengths. The complex sampling design of the NHANES minimizes selection bias, representing arguably the best available mechanism for estimating disease prevalence in the general US population.
[17] This is particularly important for studies such as this, in which the focus is on the prevention of more severe disease, such as late-stage HF. Furthermore, the comprehensive and high quality data assessments allows for a thorough examination of disease prevalence, risk factors, and socioeconomic characteristics of study participants.
In conclusion, there is a high prevalence of US adults with Stage A HF, many of whom are not being appropriately or adequately treated for their risk factors. With over 75 million people at risk for developing the lethal disease HF, primary care providers and patients need to become more aware of their risk factors and aggressively treat comorbid disease to prevent progression to symptomatic HF. Additionally, more research is needed to further understand the social and contextual factors associated with achievement of national guidelines for risk factor control and medication use. Finally, HF prevention efforts should focus on aggressive, evidence-based therapy of those with multiple uncontrolled risk factors. 
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